TAK-448

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C58H80N16O14
Molecular Weight	1225.3546
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]1(C[C@@H](O)CN1C(=O)[C@@H](CC2=CC=C(O)C=C2)NC(C)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)NNC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)NC)C(=O)N[C@@H](CC4=CNC5=C4C=CC=C5)C(N)=O

InChI

InChIKey=MWXWMWSUUYXMRA-GRKBUMBKSA-N

InChI=1S/C58H80N16O14/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C58H80N16O14
Molecular Weight	1225.3546
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	4
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24762108 | https://www.ncbi.nlm.nih.gov/pubmed/31201213 | https://www.ncbi.nlm.nih.gov/pubmed/30044673 | https://www.ncbi.nlm.nih.gov/pubmed/23027808

TAK-448 is an investigational oligopeptide analog of kisspeptin and a potent agonist of the GPR54 receptor. In animals, acute TAK-448 administration stimulates luteinizing hormone (LH)/follicle-stimulating hormone release, whereas continuous subcutaneous exposure rapidly down-regulates the pituitary-gonadal axis, with rapid reduction of testosterone levels in a dose-dependent manner. TAK-448 has exhibited potent antitumor activity in rat androgen-dependent prostate cancer models. In accordance with the T reductions, TAK-448 treatment showed also more rapid reduction in plasma prostate-specific antigen(PSA) levels. TAK-448 had been in phase II clinical trials for the treatment of prostate cancer. However, this research has been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

6 and 12 mg

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:09:14 GMT 2023` Edited by `admin` on `Sat Dec 16 09:09:14 GMT 2023`
Record UNII	YO029HR229
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TAK-448

Common Name

English

L-TRYPTOPHANAMIDE, N-ACETYL-D-TYROSYL-(4R)-4-HYDROXY-L-PROLYL-L-ASPARAGINYL-L-THREONYL-L-PHENYLALANYL-2-AZAGLYCYL-L-LEUCYL-N5-(IMINO(METHYLAMINO)METHYL)-L-ORNITHYL-

Common Name

English

(D-TYR46,D-PYA-(4)47,AZAGLY51,ARG-(ME)53)-METASTIN-(46-54)

Common Name

English

Code System Code Type Description

PUBCHEM

46700761